Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia,
Japan and Switzerland for the treatment of adult patients with unresectable or metastatic
melanoma with BRAF V600 mutation.
The main objective of this study is to find a safe and effective dose of encorafenib in
combination with binimetinib for patients who have BRAF-mutant metastatic or unresectable
melanoma with hepatic dysfunction (i.e. moderate or severe impairment).